VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Mar. 3, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences during March:
Continue Reading
Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
Continue Reading
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Feb. 8, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after
Continue Reading
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Feb. 3, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences.
Continue Reading
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 31, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the closing of its previously announced underwritten public offering of 11,035,000 common
Continue Reading
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 26, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the pricing of its underwritten public offering of 9,160,000 common shares and, in lieu of
Continue Reading
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 26, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of
Continue Reading
New Chair and CEO, Mr. Kenneth Galbraith , outlines strategic priorities for 2022 and 2023 across key clinical development activities for zanidatamab and ZW49, preclinical R&D pipeline, collaborations and partnerships Further changes to leadership team announced today in connection with Mr.
Continue Reading
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 15, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE
Continue Reading
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 6, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas , Zymeworks’ Chief Operating Officer and Chief Financial Officer, will
Continue Reading
